Sitagliptin and Ertugliflozin

What is Sitagliptin and Ertugliflozin?

Sitagliptin and Ertugliflozin is a combination medication prescribed for the management of type 2 diabetes in adults. This dual-action treatment brings together two distinct classes of oral antidiabetic agents to provide comprehensive blood glucose lowering. Sitagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, while Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Together, these components work synergistically to improve glycemic control when diet and exercise alone are insufficient, or when other medications like metformin are not adequately controlling blood sugar levels.

This combination offers a potent approach to diabetes management, targeting different pathways involved in glucose regulation. It is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.

How Does it Work?

The efficacy of Sitagliptin and Ertugliflozin stems from the distinct yet complementary mechanisms of its two active components:

• Sitagliptin (DPP-4 Inhibitor): Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme is responsible for breaking down incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, Sitagliptin increases the levels of active incretin hormones in the body. These hormones play a crucial role in glucose homeostasis by stimulating insulin release from the pancreatic beta cells in a glucose-dependent manner and reducing glucagon secretion from the pancreatic alpha cells. This leads to lower blood glucose concentrations, particularly after meals.
• Ertugliflozin (SGLT2 Inhibitor): Ertugliflozin acts on the kidneys to reduce the reabsorption of glucose. Specifically, it selectively inhibits the sodium-glucose co-transporter 2 (SGLT2) protein, which is primarily responsible for reabsorbing glucose from the filtered fluid back into the bloodstream in the renal tubules. By blocking SGLT2, Ertugliflozin causes more glucose to be excreted in the urine, thereby lowering blood glucose levels. This mechanism is independent of insulin secretion or action.

The combination of these two mechanisms provides a comprehensive approach to lowering blood sugar, addressing both insulin sensitivity/secretion and glucose excretion, making it a highly effective treatment for type 2 diabetes.

Medical Uses

Sitagliptin and Ertugliflozin is primarily indicated for improving glycemic control in adults with type 2 diabetes mellitus. It is typically prescribed as an adjunct to diet and exercise when initial monotherapy (e.g., with metformin) or dual therapy has not achieved adequate blood sugar targets. It can be used as a second-line or third-line agent, depending on individual patient needs and existing treatment regimens.

This medication is particularly beneficial for patients who may benefit from the combined effects of improved insulin sensitivity (via Sitagliptin) and increased urinary glucose excretion (via Ertugliflozin). It is crucial to note that this medication is not approved for use in patients with type 1 diabetes or for treating diabetic ketoacidosis, as its mechanisms of action are not suitable for these conditions.

Dosage

The standard dosage of Sitagliptin and Ertugliflozin is typically administered as a single oral tablet once daily, usually in the morning, with or without food. The available strengths combine different doses of Sitagliptin and Ertugliflozin, for example, 50 mg Sitagliptin with 5 mg Ertugliflozin, or 50 mg Sitagliptin with 15 mg Ertugliflozin. The specific dose prescribed will depend on the patient's individual needs, their current glycemic control, and especially their kidney function.

Before initiating treatment, and periodically thereafter, a healthcare professional will assess kidney function (e.g., estimated glomerular filtration rate, eGFR) to ensure safe and effective dosing. Patients with moderate to severe renal impairment may require dose adjustments or may not be suitable candidates for this medication. It is vital to follow the prescribing doctor's instructions precisely and not to adjust the dose without medical advice.

Side Effects

Like all medications, Sitagliptin and Ertugliflozin can cause side effects, although not everyone experiences them. Common side effects often associated with the Ertugliflozin component include urinary tract infections (UTIs) and yeast infections (genital mycotic infections) due to increased glucose in the urine. Other common side effects may include headache, nausea, diarrhea, and flu-like symptoms.

More serious, though less common, side effects warrant immediate medical attention. These include:

• Diabetic Ketoacidosis (DKA): A serious condition that can occur even with normal blood sugar levels (euglycemic DKA), characterized by nausea, vomiting, abdominal pain, and unusual tiredness.
• Kidney problems: Including acute kidney injury, especially in patients who are dehydrated or have pre-existing kidney issues.
• Pancreatitis: Symptoms include severe stomach pain that may spread to your back, with or without vomiting.
• Severe joint pain: A potential side effect associated with DPP-4 inhibitors like Sitagliptin.
• Hypoglycemia (low blood sugar): The risk of hypoglycemia increases when this medication is used in combination with insulin or sulfonylureas.
• Necrotizing fasciitis of the perineum (Fournier's gangrene): A rare but serious bacterial infection that requires urgent medical attention.
• Dehydration: Which can lead to dizziness, lightheadedness, and a drop in blood pressure.

Patients should discuss all potential side effects and concerns with their healthcare provider.

Drug Interactions

When taking Sitagliptin and Ertugliflozin, it's important to be aware of potential drug interactions that could affect its efficacy or increase the risk of side effects:

• Insulin and Insulin Secretagogues (e.g., Sulfonylureas): Concomitant use with insulin or medications that stimulate insulin release can increase the risk of hypoglycemia. A lower dose of insulin or the insulin secretagogue may be required.
• Diuretics: The diuretic effect of Ertugliflozin may be additive to that of loop or thiazide diuretics, potentially increasing the risk of dehydration and hypotension.
• Other Antidiabetic Medications: Close monitoring is essential when combining with other medications for type 2 diabetes to avoid excessive blood glucose lowering or other adverse effects.
• Medications Affecting Renal Function: Drugs that impact kidney function should be used with caution, as Ertugliflozin relies on healthy kidneys for its glucose-lowering effect.

Always inform your doctor and pharmacist about all prescription, over-the-counter, and herbal supplements you are taking to prevent adverse interactions.

FAQ

Who can take Sitagliptin and Ertugliflozin?

It is approved for adults with type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise.

Can Sitagliptin and Ertugliflozin cause weight loss?

Ertugliflozin, as an SGLT2 inhibitor, can lead to modest weight loss due to the increased excretion of glucose (and its associated calories) in the urine. Sitagliptin is generally weight-neutral.

What should I do if I miss a dose?

If you miss a dose, take it as soon as you remember, unless it's almost time for your next dose. In that case, skip the missed dose and resume your regular schedule. Do not take a double dose to make up for a missed one.

How long does it take for Sitagliptin and Ertugliflozin to work?

The effects on blood glucose can be observed relatively quickly, often within the first few weeks of treatment. However, the full benefits in terms of long-term glycemic control and A1C reduction may take several months.

Is Sitagliptin and Ertugliflozin a cure for diabetes?

No, it is not a cure for diabetes. It helps manage blood sugar levels, but it must be taken continuously as prescribed, alongside a healthy diet and regular exercise, to maintain its effects.

Products containing Sitagliptin and Ertugliflozin are available through trusted online pharmacies. You can browse Sitagliptin and Ertugliflozin-based medications at ShipperVIP or Medicenter.

Summary

Sitagliptin and Ertugliflozin offers a powerful and comprehensive approach to managing type 2 diabetes by combining two distinct mechanisms of action. By improving insulin release and increasing glucose excretion, this medication helps achieve better glycemic control. While generally effective, it's crucial to be aware of potential side effects and drug interactions. Always use this medication under the guidance of a healthcare professional, adhering to prescribed dosages and maintaining a healthy lifestyle for optimal outcomes in diabetes management.